Compare Ascendis Pharma A/S (ASND) vs Marriott International Inc (MAR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Marriott International Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Marriott International Inc trades at $379.68 (market cap $99.18B). The key difference: Marriott International Inc is far larger — about 5.6× Ascendis Pharma A/S's market cap, and Marriott International Inc pays a 0.78% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MAR | |
|---|---|---|
Market Cap | $17.74B | $99.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $402.54 |
52-Week Low | $163.32 | $255.35 |
Enterprise Value | $18.11B | $116.13B |
Dividend Yield | — | 0.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Marriott International (MAR) trades at $376.11, up 0.98% today, with a bearish technical signal and a consensus price target of $386.42. Recent earnings show mixed results, with Q1 2026 beating expectations but Q4 2025 missing. The company maintains strong revenue growth, reaching $26.19B in 2025, and a net income margin of 9.72%. Key developments include the launch of Ask Bonvoy AI and reaching 10,000 properties globally, though hotel owners are pushing back on loyalty program terms.
Outlook is cautiously optimistic with upside to the consensus target, supported by solid fundamentals and strategic initiatives. Risks include rising debt-to-asset ratio (58.83% in 2025), competitive pressures, and potential travel demand volatility. Analyst sentiment is mixed with 44% buy ratings, but technical indicators suggest near-term bearish pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
